Cytokinetics to report Q1 2026 earnings on May 5, followed by a management call.

Cytokinetics, a biopharmaceutical company specializing in cardiovascular treatments, will announce its first quarter 2026 financial results on May 5 at 4:00 PM ET. After the earnings release, senior management will hold a conference call to discuss the results and provide business updates. The company is known for its cardiac muscle therapies, including the approved drug MYQORZO® (aficamten) for obstructive hypertrophic cardiomyopathy, and is developing other treatments for heart failure. Investors can access the live webcast and replay on Cytokinetics’ website.